Newtyn Management, LLC Galapagos Nv Transaction History

Newtyn Management, LLC

$458 Million
Q2 2024

A detailed history of Newtyn Management, LLC transactions in Galapagos Nv stock. As of the latest transaction made, Newtyn Management, LLC holds 500,000 shares of GLPG stock, worth $13.8 Million. This represents 2.7% of its overall portfolio holdings.

Number of Shares

500,000

Previous 366,000 36.61%

Holding current value

$13.8 Million

Previous $11.8 Million 5.13%

% of portfolio

2.7%

Previous 2.54%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$24.78 - $32.48 $3.32 Million - $4.35 Million	134,000 Added 36.61%	500,000 $12.4 Million
Q1 2024 May 15, 2024	BUY	$32.2 - $42.44 $4.76 Million - $6.28 Million	147,913 Added 67.82%	366,000 $11.8 Million
Q4 2023 Feb 14, 2024	SELL	$31.87 - $40.71 $1.81 Million - $2.32 Million	-56,913 Reduced 20.7%	218,087 $8.87 Million
Q3 2023 Nov 14, 2023	BUY	$34.17 - $42.98 $170,850 - $214,899	5,000 Added 1.85%	275,000 $9.5 Million
Q2 2023 Aug 14, 2023	BUY	$37.4 - $44.52 $64,253 - $76,485	1,718 Added 0.64%	270,000 $11 Million
Q1 2023 May 15, 2023	BUY	$36.5 - $48.0 $484,793 - $637,536	13,282 Added 5.21%	268,282 $10.4 Million
Q4 2022 Feb 14, 2023	BUY	$37.44 - $46.51 $2.81 Million - $3.49 Million	75,000 Added 41.67%	255,000 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$42.27 - $57.6 $422,700 - $576,000	10,000 Added 5.88%	180,000 $7.68 Million
Q2 2022 Aug 15, 2022	BUY	$52.3 - $71.59 $2.96 Million - $4.05 Million	56,600 Added 49.91%	170,000 $9.49 Million
Q1 2022 May 16, 2022	BUY	$51.32 - $68.5 $5.82 Million - $7.77 Million	113,400 New	113,400 $7.03 Million

Others Institutions Holding GLPG

# of Institutions

Shares Held

17.4M

Call Options Held

10.4K

Put Options Held

33.1K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.82B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Newtyn Management, LLC with notifications on news.

Account

Newtyn Management, LLC Galapagos Nv Transaction History